1. Home
  2. BAFN vs JSPR Comparison

BAFN vs JSPR Comparison

Compare BAFN & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BayFirst Financial Corp.

BAFN

BayFirst Financial Corp.

HOLD

Current Price

$6.32

Market Cap

26.6M

Sector

Finance

ML Signal

HOLD

Logo Jasper Therapeutics Inc.

JSPR

Jasper Therapeutics Inc.

HOLD

Current Price

$0.79

Market Cap

22.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BAFN
JSPR
Founded
1999
2018
Country
United States
United States
Employees
N/A
22
Industry
Savings Institutions
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.6M
22.9M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
BAFN
JSPR
Price
$6.32
$0.79
Analyst Decision
Buy
Analyst Count
0
11
Target Price
N/A
$15.50
AVG Volume (30 Days)
20.9K
2.2M
Earning Date
04-30-2026
05-12-2026
Dividend Yield
1.00%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.26
$0.32
52 Week High
$11.34
$3.14

Technical Indicators

Market Signals
Indicator
BAFN
JSPR
Relative Strength Index (RSI) 57.05 63.01
Support Level $5.83 $0.79
Resistance Level $6.96 $1.03
Average True Range (ATR) 0.53 0.08
MACD 0.03 0.00
Stochastic Oscillator 36.02 93.26

Price Performance

Historical Comparison
BAFN
JSPR

About BAFN BayFirst Financial Corp.

BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.

About JSPR Jasper Therapeutics Inc.

Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.

Share on Social Networks: